Remove Licensing Remove Molecular Biology Remove Protein Expression Remove Treatment
article thumbnail

BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

The Pharma Data

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Few details of the deal were disclosed in the announcement. provided an update on its ongoing NASH program.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Thereafter, there will be two presentations, which are: Jan Terje Andersen, PhD, Professor, Department of Pharmacology, University of Oslo; Research Group Leader, Department of Immunology, Oslo University Hospital, on: ‘Biology-based engineering of versatile antibody and albumin technologies’.